False
October 12, 2026
“Caribou’s story has taken a heartbreaking turn,” says CEO Rachel Haurwitz, with the CRISPR-focused biotech set to discontinue vispa-cel and CB-011, and reduce its workforce
2 min read
October 12, 2026
Bayer plans a $2.2 billion Ohio campus, Genentech breaks ground in Oregon, and new investments support vaccine production, downstream processing, and manufacturing in orbit
5 min read
October 12, 2026
SOTIO Biotech’s CSO explains why drug developers should test their weakest assumptions early, how she builds innovative teams, and where ADCs could go next
8 min read
October 8, 2026
Adicet Bio reports 12-month remission and renal response data for its allogeneic gamma delta CAR T therapy
2 min read
October 8, 2026
We asked the 2026 Power List whether newer modalities have eclipsed small molecules – and where the traditional mainstay still wins
4 min read
October 7, 2026
Catalent’s John Tomtishen discusses his path into cell therapy and the evolving approaches to CMC, manufacturing, and commercialization
1 min read
October 7, 2026
No autoimmune disease flares occurred across 14 pregnancies after CAR T-cell therapy, with 8 healthy babies born and 5 pregnancies ongoing.
3 min read
October 7, 2026
Persistent CAR T cells and widespread immune disruption may help explain a rare form of severe intestinal inflammation after BCMA-directed therapy
3 min read
October 7, 2026
Mayo Clinic and Thermo Fisher launch a large-scale multi-omics resource designed to reveal disease before symptoms appear
2 min read
October 6, 2026
Early developers do not need a finalized commercial process before first-in-human studies, but they do need a clear plan for managing cost, scalability, comparability, and future manufacturing changes
7 min read
False